Vestaron Announces First Product Submission to EPA
Published: Jul 17, 2012
KALAMAZOO, MI--(Marketwire - July 17, 2012) -
This new biopesticide provides levels of control expected from commercial insecticides. The product will give specialty crop growers not only a new option for control of a major class of insect pests, but also a new mode of action to strengthen their resistance management strategy.
"It is exciting to submit a biopesticide product with a novel mode of action that can be integrated into insect resistance management programs," said Robert Kennedy, Ph.D., Vestaron's Chief Scientific Officer. "There are still many situations in which new solutions are needed for successful insect control."
The bioinsecticide recently submitted to the EPA is the first portfolio product that Vestaron has developed from its library of novel natural peptides. The company recently received notification that the submission had just passed through both the Completeness Screen and Submission Readiness Team (SRT) review. The SRT is a technical screen of the submission to determine if it is complete for routing for scientific review. This starts the clock for the legislatively mandated 16 month review.
About Vestaron Corporation
Vestaron is developing a new generation of insecticides using natural peptides. Products under development have a unique mode of action, are highly effective against insects and related pests and are harmless to non-target species, including humans. Target markets include agriculture, animal health and specialty non-crop uses such as household insects. Vestaron cleantech products will be ideally suited for the environmentally conscious twenty-first century. For more information visit www.vestaron.com.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. Vestaron's actual results may differ materially from Vestaron's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to Vestaron's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of Vestaron's intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.